tradingkey.logo
tradingkey.logo
Search

Pharvaris NV

PHVS
Add to Watchlist
32.620USD
-1.260-3.72%
Close 07-31 16:00ETQuotes delayed by 15 min
2.27BMarket Cap
LossP/E TTM

Pharvaris NV

32.620
-1.260-3.72%
View Detailed Chart
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-3.72%

5 Days

-4.54%

1 Month

-3.92%

6 Months

+20.59%

Year to Date

+17.55%

1 Year

+63.10%

Key Figures
33.780Open
33.780High
507.25KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.78%Turnover Ratio
33.880Prev. Close
32.000Low
13.20MTurnover
LossP/E Static
6.80P/B
0.00%Div Yield TTM
-66.38%ROA
33.33052wk High
1.40Volume Ratio
-100.88MNet Profit
65.21MShares
-2.3543EPS TTM
-2.35Beta
-73.02%ROE
15.51052wk Low
5.25%Amplitude
--Gross Margin
2.27BMarket Cap
0.56Reward/Risk
3.53%Risk Rate

Pharvaris NV News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 15 analysts
Buy
Current Rating
47.600
Target Price
+45.92%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Pharvaris NV
PHVS
15
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99

Indicators

Indicators
Sell(3)
Neutral(3)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.589
Neutral
RSI(14)
45.261
Neutral
STOCH(KDJ)(9,3,3)
28.793
Neutral
ATR(14)
1.493
High Vlolatility
CCI(14)
-178.507
Sell
Williams %R
82.486
Oversold
TRIX(12,20)
0.043
Sell
StochRSI(14)
11.966
Sell
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
33.347
Sell
MA10
33.653
Sell
MA20
34.227
Sell
MA50
32.705
Sell
MA100
30.527
Buy
MA200
27.962
Buy

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Pharvaris NV Info

Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
Ticker SymbolPHVS
CompanyPharvaris NV
CEOModig (Berndt B.A.E)
Websitehttps://pharvaris.com/

Shareholders

Shareholders
Shareholders
Proportion
General Atlantic LLC
11.53%
Fidelity Management & Research Company LLC
9.19%
Foresite Capital Management, LLC
6.86%
VenBio Partners LLC
6.66%
Viking Global Investors LP
5.24%
Other
60.52%

FAQs

What is the current price of Pharvaris NV (PHVS)?

The current price of Pharvaris NV (PHVS) is 32.62.

What is the symbol of Pharvaris NV?

The ticker symbol of Pharvaris NV is PHVS.

What is the 52-week high of Pharvaris NV?

The 52-week high of Pharvaris NV is 33.33.

What is the 52-week low of Pharvaris NV?

The 52-week low of Pharvaris NV is 15.51.

What is the market capitalization of Pharvaris NV?

The market capitalization of Pharvaris NV is 2.13B.

Is Pharvaris NV (PHVS) currently rated as Buy, Hold, or Sell?

According to analysts, Pharvaris NV (PHVS) has an overall rating of Buy, with a price target of 47.60.

What is the Earnings Per Share (EPS TTM) of Pharvaris NV (PHVS)?

The Earnings Per Share (EPS TTM) of Pharvaris NV (PHVS) is -3.49.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.